Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haesook T Kim

Showing results (101-110 of 191) with videos related to

Pageof 20
Sort By:
Leukemia & Lymphoma|October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Haematologica|August 26, 2021
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformationHaesook T Kim, Peter O Baker, Erin Parry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2011
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor graftsYi-Bin Chen, Julie Aldridge, Haesook T Kim, et al.
Blood|March 23, 2006
Rituximab for steroid-refractory chronic graft-versus-host diseaseCorey Cutler, David Miklos, Haesook T Kim, et al.
Blood Advances|February 9, 2021
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experienceKatie Maurer, Anna Saucier, Haesook T Kim, et al.
Blood|June 20, 2012
A disease risk index for patients undergoing allogeneic stem cell transplantationPhilippe Armand, Christopher J Gibson, Corey Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2010
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantationPhilippe Armand, Haesook T Kim, Joanna Rhodes, et al.
Blood|July 18, 2013
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trialCorey Cutler, Haesook T Kim, Bhavjot Bindra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand, Haesook T Kim, Vincent T Ho, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II TrialJohn Koreth, Haesook T Kim, Paulina B Lange, et al.
Pageof 20

Showing results (101-110 of 191) with videos related to

Sort By:
Pageof 20
Leukemia & Lymphoma|October 17, 2018
Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia<sup>.</sup>Matthew S Davids, Haesook T Kim, Lijian Yu, et al.
Haematologica|August 26, 2021
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformationHaesook T Kim, Peter O Baker, Erin Parry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2011
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor graftsYi-Bin Chen, Julie Aldridge, Haesook T Kim, et al.
Blood|March 23, 2006
Rituximab for steroid-refractory chronic graft-versus-host diseaseCorey Cutler, David Miklos, Haesook T Kim, et al.
Blood Advances|February 9, 2021
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experienceKatie Maurer, Anna Saucier, Haesook T Kim, et al.
Blood|June 20, 2012
A disease risk index for patients undergoing allogeneic stem cell transplantationPhilippe Armand, Christopher J Gibson, Corey Cutler, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2010
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantationPhilippe Armand, Haesook T Kim, Joanna Rhodes, et al.
Blood|July 18, 2013
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trialCorey Cutler, Haesook T Kim, Bhavjot Bindra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcomePhilippe Armand, Haesook T Kim, Vincent T Ho, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II TrialJohn Koreth, Haesook T Kim, Paulina B Lange, et al.
Pageof 20